The introduction of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication appears to offer impressive improvements in body shedding compared to current therapies. Preliminary patient studies have shown significant decreases in body fat percen